SYNBIO Business Summary

Synbio Tech Inc. (1295.TWO) operates a vertically integrated biotechnology business model centered on the research, manufacturing, and global distribution of functional probiotics and lactic acid bacteria. The company generates revenue through three core segments: Human Health (probiotic strains and OEM/ODM supplements), Animal Nutrition (feed additives for livestock and aquaculture), and Plant Health (silage fermentation starters). Its competitive advantage is derived from the proprietary SYNTEK® thorough technology platform, which enhances strain viability and functional efficacy through specialized selection, fermentation, and stabilization processes. In the regional market, Synbio Tech competes directly with Grape King Bio (1707.TW), Bio-Resource Inc. (3229.TW), and Glac Biotech (6553.TW). Synbio positions itself as a high-end, R&D-intensive supplier, leveraging an extensive microbial strain bank and international certifications to capture market share in the premium nutraceutical and agricultural sectors. The company is led by Chairman Yang Lian-chuan, a veteran in the biotechnology sector who has overseen the firm’s expansion into international markets and its listing on the TPEx. General Manager Hsu Ting-hsuan serves as the key executive driving operational strategy and business development, focusing on scaling the company’s manufacturing capabilities and clinical research initiatives. The leadership team is characterized by a strong background in fermentation science and industrial microbiology, supported by a board that includes strategic investors from the Taiwanese food and life sciences industries. This executive core has successfully transitioned Synbio from a domestic supplier to a global contender, emphasizing rigorous quality control and a science-led approach to product development that targets high-growth markets in North America, Europe, and Southeast Asia.